Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
复制标题
DOI：
10.1002/cyto.b.21636
复制
发表时间：
2018-09-01
影响因子：
3.4
通讯作者：
Hundemer, Michael
中科院分区：
文献类型：
--
作者：
Kriegsmann, Katharina;Dittrich, Tobias;Hundemer, Michael
BackgroundRecent approaches in multiple myeloma (MM) treatment have targeted CD38. As antigen expression levels on plasma cells (PCs) were demonstrated to affect response to monoclonal antibody (mAb) treatment, a precise characterization of PC phenotype is warranted.MethodsAnti-CD38 mAb (isatuximab) was tested for antibody-dependent cellular cytotoxicity (ADCC) in MM cell lines. Quantification of the number of sites (NOS) of CD38 on bone marrow PCs and other immune cells obtained from light chain (AL) amyloidosis (n=46) and smoldering multiple myeloma (SMM) patients (n=19) was performed with two different quantitative flow cytometry (QFCM) applications.ResultsADCC activity of isatuximab was observed in cell lines with >100 x 10(3) CD38-NOS only. The average PC CD38-NOS was 15353 x 10(3) in AL amyloidosis and 138.7 +/- 53 x 10(3) in SMM patients. Eight (17%) AL amyloidosis and 4 (21%) SMM patients showed a PC CD38-NOS level
